Marshall Wace North America’s Clementia Pharmaceuticals Inc. CMTA Stock Holding History

Marshall Wace North America’s Portfolio CMTA Stock Details CMTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-1,685	Closed	-$44K	–	1873
2019 Q1	$44K	Buy	+1,685	New	+$31.5K	﹤0.01%	1290
2018 Q2	–	Sell	-27,113	Closed	-$411K	–	1888
2018 Q1	$411K	Buy	+27,113	New	+$441K	﹤0.01%	1194
2017 Q4	–	Sell	-94,682	Closed	-$1.61M	–	1751
2017 Q3	$1.61M	Buy	+94,682	New	+$1.55M	0.01%	851

Marshall Wace North America's CMTA Position: Q2 2019 in Review

Marshall Wace North America sold out of Clementia Pharmaceuticals Inc. (CMTA) in Q2 2019, closing a stake of 1,685 shares — an estimated $44K sold.

Marshall Wace North America first reported a position in CMTA in Q3 2017 and held it in 3 quarters. The position peaked at $1.61M in Q3 2017. 0 funds tracked by Wall St. Rank hold CMTA as of Q2 2019.

Marshall Wace North America reported no remaining Clementia Pharmaceuticals Inc. position as of Q2 2019 after selling out during the quarter.
Marshall Wace North America sold 1,685 Clementia Pharmaceuticals Inc. shares in Q2 2019, an estimated $44K.
Marshall Wace North America first reported a position in Clementia Pharmaceuticals Inc. in Q3 2017 and held it in 3 quarters.
Marshall Wace North America's Clementia Pharmaceuticals Inc. position peaked at $1.61M in Q3 2017.
0 funds tracked by Wall St. Rank held Clementia Pharmaceuticals Inc. as of Q2 2019.

Based on Marshall Wace North America's 13F filing for Q2 2019, filed 14 Aug 2019.